I get lots of shareholders contacting me asking about getting access to Zantrene (bisantrene) under compassionate use for their friends and family and all of the stories are terrible. The potential of Zantrene to help make a difference certainly keeps me motivated to get it back onto the market as soon as we can.
Ann: First Patient Dosed in Phase 1b/2 AML Trial, page-68
-
- There are more pages in this discussion • 178 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $287.1M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2348 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 2344 | 2 |
View Market Depth
| Last trade - 10.00am 16/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable